X4 Pharmaceuticals (XFOR) Fundamental Analysis: Revenue, Earnings & Valuation

5.19 / 10

Netural

Fundamental assessment yields a 5.19/10 score, indicating average strength. Positive drivers include PB‑ROE, cash‑to‑market, revenue‑to‑market and strong revenue growth, while asset‑to‑market and margin metrics drag performance. Overall, the balance sheet is solid but profitability and tax efficiency raise concerns.

Analysis Checks(7/10)

Revenue-MV

Value-3.71

Score3/3

Weight38.31%

1M Return9.01%

Total operating revenue (YoY growth rate %)

Value1273.21

Score3/3

Weight4.73%

1M Return1.54%

Inventory turnover ratio

Value1.58

Score2/3

Weight-3.41%

1M Return-1.21%

Gross profit margin (%)

Value83.60

Score0/3

Weight-17.76%

1M Return-7.24%

PB-ROE

Value1.33

Score2/3

Weight22.97%

1M Return6.97%

Income tax / Total profit (%)

Value-0.05

Score1/3

Weight-1.40%

1M Return-0.50%

Fixed assets turnover ratio

Value73.30

Score3/3

Weight3.13%

1M Return1.06%

Cost of sales ratio (%)

Value16.40

Score2/3

Weight-11.66%

1M Return-4.42%

Asset-MV

Value-0.55

Score1/3

Weight43.54%

1M Return11.07%

Cash-MV

Value0.02

Score2/3

Weight21.56%

1M Return5.94%

Is XFOR fundamentally strong?

XFOR scores 5.19/10 on fundamentals and holds a Fair valuation at present. Backed by its -75.99% ROE, -225.55% net margin, -4.99 P/E ratio, 2.12 P/B ratio, and 66.55% earnings growth, these metrics solidify its Netural investment rating.